2021 Predictions: a BioCentury survey

While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one vaccination at a time. 

BioCentury surveyed members of its scientific advisory board and select other KOLs from December 2 to 8 about their expectations for innovation, clinical readouts, COVID-19 and the financing and dealmaking landscape in 2021.  The respondents were a cohort of  18 biopharma C-suite executives, pharma R&D heads and investors based in the U.S., Europe and China. Responses were anonymous...